Wugen
4 known investors
Allotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
BiotechMedical Devices
Investors · 4
In the news
- Allotera Therapeutics, formerly Wugen, raises $35 million for blood cancer trial - St. Louis Business Journalbizjournals.com · 2026
- Allotera Therapeutics Raises $35M in Fundingfinsmes.com · 2026
- Wugen raises $115m for trial of T-cell cancer therapyclinicaltrialsarena.com · 2025
- Wugen Raises $115M in Fundingfinsmes.com · 2025
- Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T | BioPharma Divebiopharmadive.com · 2025
- Wugen - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021